Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Recent & Breaking News (NDAQ:TRAW)

Investor Network: Onconova Therapeutics Inc. to Host Earnings Call

Accesswire August 15, 2017

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results

GlobeNewswire August 15, 2017

Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2017 Financial Results

GlobeNewswire August 8, 2017

Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies”

GlobeNewswire July 25, 2017

Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid

GlobeNewswire June 26, 2017

Onconova Therapeutics to Present at the BIO International Convention

GlobeNewswire June 13, 2017

Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire June 5, 2017

Onconova Announces Multiple Presentations at the 22nd Congress of the European Hematology Association

GlobeNewswire May 22, 2017

Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 18, 2017

Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results

GlobeNewswire May 15, 2017

Investor Network: Onconova Therapeutics Inc. to Host Earnings Call

Accesswire May 15, 2017

Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2017 Financial Results

GlobeNewswire May 4, 2017

Onconova to Present Rigosertib Clinical Data at the 14th International Symposium on Myelodysplastic Syndromes

GlobeNewswire May 1, 2017

Onconova Therapeutics Announces Closing of Public Offering of Common Stock

GlobeNewswire April 26, 2017

Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC

GlobeNewswire April 26, 2017

Mid-Afternoon Market Update: Crude Oil Down 2.5%; Werner Enterprises Shares Spike Higher

Benzinga.com  April 21, 2017

15 Biggest Mid-Day Losers For Friday

Benzinga.com  April 21, 2017

Onconova Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire April 21, 2017

Onconova Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire April 20, 2017

Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting

GlobeNewswire April 4, 2017